Polygenic Score (PGS) ID: PGS004139

Predicted Trait
Reported Trait Prostate cancer
Mapped Trait(s) prostate carcinoma (EFO_0001663)
Released in PGS Catalog: Dec. 19, 2023
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name sbayesr.auto.GCST006085.Prostate_cancer
Development Method
Name SBayesR-auto
Parameters auto with --robust
Variants
Original Genome Build GRCh38
Number of Variants 945,385
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000517
Citation (link to publication) Monti R et al. Am J Hum Genet (2024)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
140,254 individuals (100%)
Score Development/Training
European: 100%
9,671 individuals (100%)
PGS Evaluation
European: 66.7%
South Asian: 33.3%
6 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST006085
Europe PMC: 29892016
140,254 individuals European NR
Score Development/Training
Study Identifiers Sample Numbers Sample Ancestry Cohort(s) Phenotype Definitions & Methods Age of Study Participants Participant Follow-up Time Additional Ancestry Description Additional Sample/Cohort Information
9,671 individuals,
100.0 % Male samples
European UKB

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM019539 PSS011221|
European Ancestry|
68,516 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 1.83755
β: 0.60843
AUROC: 0.67 0 beta = log(or)/sd_pgs
PPM019540 PSS011232|
European Ancestry|
171,474 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 2.10912
β: 0.74627
AUROC: 0.7 0 beta = log(or)/sd_pgs
PPM019541 PSS011245|
South Asian Ancestry|
19,738 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 2.09532
β: 0.73971
AUROC: 0.71 0 beta = log(or)/sd_pgs
PPM019542 PSS011261|
European Ancestry|
31,410 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 1.94637
β: 0.66597
AUROC: 0.68 0 beta = log(or)/sd_pgs
PPM019543 PSS011289|
South Asian Ancestry|
4,976 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 2.33868
β: 0.84959
AUROC: 0.73 0 beta = log(or)/sd_pgs
PPM019544 PSS011274|
European Ancestry|
41,305 individuals
PGP000517 |
Monti R et al. Am J Hum Genet (2024)
Reported Trait: Prostate cancer OR: 2.05644
β: 0.72098
AUROC: 0.69 0 beta = log(or)/sd_pgs

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS011274
[
  • 2,417 cases
  • , 38,888 controls
]
,
100.0 % Male samples
European UKB
PSS011245
[
  • 95 cases
  • , 19,643 controls
]
,
100.0 % Male samples
South Asian G&H
PSS011221
[
  • 2,227 cases
  • , 66,289 controls
]
,
100.0 % Male samples
European EB
PSS011289
[
  • 110 cases
  • , 4,866 controls
]
,
100.0 % Male samples
South Asian UKB
PSS011261
[
  • 2,242 cases
  • , 29,168 controls
]
,
100.0 % Male samples
European HUNT
PSS011232 C3_PROSTATE, ICD10: C61, ICD9: 185
[
  • 13,606 cases
  • , 157,868 controls
]
,
100.0 % Male samples
European FinnGen